Breakthrough in Cardiac Recovery: Weight-Loss Drugs May Prevent Fatal Heart Attack Complications
New UK study finds GLP-1 drugs like Ozempic and Wegovy could reduce risk of tissue damage in heart attack patients, offering hope for better recovery.
In a groundbreaking discovery, researchers in the UK have found that weight-loss drugs may hold the key to preventing potentially fatal complications for heart attack survivors. The latest animal model trials have revealed that medications such as Ozempic and Wegovy, which are used to treat obesity, could significantly reduce the risk of a devastating condition known as 'no-reflow' that affects up to half of the 100,000 people who suffer a heart attack in the UK each year.
The 'no-reflow' phenomenon is a major concern for cardiologists, as it can lead to further tissue damage and complications in the aftermath of a heart attack. When blood flow is restored to the heart after a heart attack, this condition can prevent oxygen-rich blood from fully reaching all the affected areas, exacerbating the initial injury.
{{IMAGE_PLACEHOLDER}}Source: The Guardian
